Antigen binding molecules and methods of use thereof

1. An isolated antigen binding molecule that specifically binds to a polypeptide comprising the amino acid sequence GGGS (SEQ ID NO: 1) wherein the antigen binding molecule comprises a first, second or third set of complementarity determining regions (CDRs), wherein:

the first set of CDRs comprises:

a. a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 26;

b. a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27;

c. a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 19;

d. a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 8;

e. a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 9; and

f. a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 10, the second set of CDRs comprises:

g. a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 28;

h. a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29;

i. a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 22;

j. a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 11;

k. a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 12; and

l. a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 13, third set of CDRs comprises:

m. a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 30;

n. a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31;

o. a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 25;

p. a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 14;

q. a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 15; and

r. a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 16.

2. The isolated antigen binding molecule of claim 1 , wherein the polypeptide is a chimeric antigen receptor (CAR).

3. The antigen binding molecule of claim 1 , comprising a heavy chain variable region (VH) amino acid sequence that is a VH sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6;

wherein the VH sequence of SEQ ID NO: 2 comprises the VH CDR1, VH CDR2 and VH CDR3 from the first set of CDRs;

wherein the VH sequence of SEQ ID NO: 4 comprises the VH CDR1, VH CDR2 and VH CDR3 from the second set of CDRs; and

wherein the VH sequence SEQ ID NO: 6 comprises the VH CDR1, VH CDR2 and VH CDR3 from the third set of CDRs.

4. The antigen binding molecule of claim 1 , comprising a light chain variable region (VL) amino acid sequence that is a VL sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 5, and SEQ ID NO: 7;

wherein the VL sequence of SEQ ID NO: 3 comprises the VL CDR1, VL CDR2 and VL CDR3 from the first set of CDRs;

wherein the VL sequence of SEQ ID NO: 5 comprises the VL CDR1, VL CDR2 and VL CDR3 from the second set of CDRs; and

wherein the VL sequence SEQ ID NO: 7 comprises the VL CDR1, VL CDR2 and VL CDR3 from the third set of CDRs.

5. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises:

(a) a VH comprising the amino acid sequence of SEQ ID NO: 2;

(b) a VL comprising the amino acid sequence of SEQ ID NO: 3; and

wherein the antigen binding molecule further comprises the first set of CDRs.

6. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises:

(a) a VH comprising the amino acid sequence of SEQ ID NO: 4;

(b) a VL comprising the amino acid sequence of SEQ ID NO: 5; and

wherein the antigen binding molecule further comprises the second set of CDRs.

7. The antigen binding molecule of claim 1 , wherein the antigen binding molecule comprises:

(a) a VH comprising the amino acid sequence of SEQ ID NO: 6;

(b) a VL comprising the amino acid sequence of SEQ ID NO: 7; and

wherein the antigen binding molecule further comprises the third set of CDRs.

8. The antigen binding molecule of claim 1 , a wherein the antigen binding molecule is conjugated to a detectable label, and wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.

9. The antigen binding molecule of claim 8 , wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP, Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoerythrin (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.